During the quarter, the commercial production commenced at greenfield manufacturing facility for industrial Packaging products at Vizag.

India’s pharma major, Sun Pharmaceutical Industries has received the approval of US drug regulator for YONSA, a combination medication to treat metastatic castration-resistant prostate cancer (mCRPC) patients.

These are the stock where short build up position is seen

These are the stocks where long build up position is seen

Going ahead, Tuesday’s session low of 10,491 would act as an immediate support level, and a follow-through move below this level could lead to further downside up to the level of 10,440, which is 50 per cent retracement level of the recent rise from the March low. Stocks in news: Sun Pharmaceuticals, Minda Industries, Gravita and Majesco.

Indian benchmark indices are likely to witness quiet to modestly negative start to the trading session as cues from Asian peers are not encouraging. The trading of Nifty 50 index futures on the Singapore stock exchange indicates that the Nifty may open down by 20 points at 10,529.  

In a significant development, Bharti Group sold off its entire stake of 13.64 per cent in Kishori Biyani-led Future Enterprises, making an exit for an estimated sum of Rs. 240 crore on Tuesday. 

The EBITDA for the quarter declined by 2 per cent QoQ to Rs.63 crore in Q4FY18 as compared with Rs.65 crore in Q3FY18. The EBITDA margin expanded by 170 bps to 10.1 per cent for Q4FY18. 

The reported net profit for the quarter came in at Rs 139.95 crore, an increase of 122.5 per cent YoY. This includes exceptional gain of Rs 38.24 crore.

The share price of Dabur India suffered a setback in Tuesday ’s trading as reports surfaced that assets worth Rs 21 crore have been seized from Pradip Burman, the director of the company.